47.24

1.69% -0.81

After Hours: 46.81 -0.43 -0.91%

Supernus Pharmaceuticals Inc (SUPN)

Overview News Price History Option Chain Financials Why SUPN Down? Discussions Forecast

Supernus Pharmaceuticals Inc stock is traded at $47.24, with a volume of 878.47K. It is down -1.69% in the last 24 hours and up +5.56% over the past month. Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Previous Close:

$48.05

Open:

$47.62

24h Volume:

878.47K

Relative Volume:

1.28

Market Cap:

$2.74B

Revenue:

$776.83M

Net Income/Loss:

$-29.02M

P/E Ratio:

-92.27

EPS:

-0.512

Net Cash Flow:

$82.25M

1W Performance:

+0.94%

1M Performance:

+5.56%

6M Performance:

-4.10%

1Y Performance:

+47.72%

1-Day Range:

$46.76

$48.12

1-Week Range:

$45.99

$48.12

52-Week Range:

$31.35

$59.68

Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile

Name

Supernus Pharmaceuticals Inc

Sector

Healthcare (1100)

Industry

Drug Manufacturers - Specialty & Generic (86)

Phone

301-838-2500

Address

9715 KEY WEST AVENUE, ROCKVILLE, MD

Employee

778

Twitter

@Supernus_Pharma

Next Earnings Date

2026-08-04

Latest SEC Filings

SUPN's Discussions on Twitter

Compare SUPN vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SUPN Supernus Pharmaceuticals Inc	47.24	2.70B	776.83M	-29.02M	82.25M	-0.512
TAK Takeda Pharmaceutical Co Adr	16.89	50.65B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.72	41.09B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	35.29	39.45B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	75.42	30.13B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	547.25	23.00B	3.17B	1.29B	1.01B	27.09

Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-25	Upgrade	Piper Sandler	Neutral → Overweight
Jul-30-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-19-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-06-25	Initiated	Cantor Fitzgerald	Overweight
Sep-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Jan-03-23	Resumed	Jefferies	Buy
Dec-01-21	Resumed	Jefferies	Buy
Apr-13-21	Upgrade	Jefferies	Hold → Buy
Jun-16-20	Upgrade	Piper Sandler	Neutral → Overweight
Jun-15-20	Resumed	Jefferies	Hold
Nov-08-19	Downgrade	Berenberg	Buy → Hold
Nov-07-19	Downgrade	Stifel	Buy → Hold
Nov-06-19	Downgrade	Jefferies	Buy → Hold
Nov-12-18	Reiterated	B. Riley FBR	Buy
Jan-18-18	Reiterated	B. Riley FBR, Inc.	Buy
Dec-28-17	Reiterated	B. Riley FBR, Inc.	Buy
Dec-04-17	Upgrade	Janney	Neutral → Buy
Nov-08-17	Upgrade	Stifel	Hold → Buy
Oct-19-17	Initiated	FBR & Co.	Buy
Sep-19-17	Downgrade	Stifel	Buy → Hold
Jul-17-17	Downgrade	Piper Jaffray	Overweight → Neutral
Jul-14-17	Initiated	Janney	Neutral
Jun-01-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-18-16	Downgrade	Northland Capital	Outperform → Market Perform
Jul-18-16	Downgrade	Piper Jaffray	Overweight → Neutral
Feb-08-16	Upgrade	Jefferies	Hold → Buy
Nov-05-15	Reiterated	Northland Capital	Outperform
Oct-28-15	Initiated	Northland Capital	Outperform

View All

Supernus Pharmaceuticals Inc Stock (SUPN) Latest News

Jun 29, 2026

Discipline and Rules-Based Execution in SUPN Response - Stock Traders Daily

Jun 29, 2026

Jun 27, 2026

Price to book forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView

Jun 27, 2026

Jun 26, 2026

Enterprise value to EBIT forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView

Jun 26, 2026

Enterprise value to EBIT forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2 - TradingView

Jun 26, 2026

Q3 2025 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus

Jun 26, 2026

Supernus Pharmaceuticals, Inc. Actuals & Estimates (BX:S49) - TradingView

Jun 26, 2026

Price to earnings forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView

Jun 26, 2026

Supernus Pharmaceuticals, Inc. Actuals & Estimates (LSE:0LB2) - TradingView

Jun 26, 2026

S49 Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Jun 25, 2026

Enterprise value to EBITDA forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2 - TradingView

Jun 25, 2026

Price to sales forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2 - TradingView

Jun 25, 2026

Price to earnings forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2 - TradingView

Jun 25, 2026

Enterprise value to revenue forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView

Jun 25, 2026

Jun 24, 2026

Q4 2025 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus

Jun 24, 2026

Jun 23, 2026

Supernus Pharmaceuticals Insiders Sold US$2.1m Of Shares Suggesting Hesitancy - 富途牛牛

Jun 23, 2026

Branded Pharmaceuticals Stocks Q1 Teardown: Supernus Pharmaceuticals (NASDAQ:SUPN) Vs The Rest - Yahoo Finance

Jun 23, 2026

Jun 20, 2026

How Strong Quarterly Results and MERGE Partnership Will Impact Supernus Pharmaceuticals (SUPN) Investors - Sahm

Jun 20, 2026

Jun 18, 2026

Supernus Pharmaceuticals shareholders approve director elections and key proposals - Investing.com UK

Jun 18, 2026

Supernus Pharmaceuticals shareholders approve director elections and key proposals By Investing.com - Investing.com Nigeria

Jun 18, 2026

Supernus Investors Approve Directors, Pay and Incentive Plan - TipRanks

Jun 18, 2026

Supernus (NASDAQ: SUPN) holders approve directors, say-on-pay and equity plan - Stock Titan

Jun 18, 2026

Jun 17, 2026

Behavioral Patterns of SUPN and Institutional Flows - Stock Traders Daily

Jun 17, 2026